
Susan K Bowles

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7574127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interventions to reduce benzodiazepine and sedative-hypnotic drug use in acute care hospitals: A scoping review. Research in Social and Administrative Pharmacy, 2022, 18, 2874-2886.	1.5	4
2	Why I Got My COVID Shot. Canadian Journal of Hospital Pharmacy, 2022, 75, 3.	0.1	0
3	Potentially Inappropriate Drug Duplication in a Cohort of Older Adults with Dementia. Current Therapeutic Research, 2021, 95, 100644.	0.5	2
4	An examination of three prescribing cascades in a cohort of older adults with dementia. BMC Geriatrics, 2021, 21, 297.	1.1	14
5	Review of the top 5 geriatrics studies of 2018-2019. Canadian Pharmacists Journal, 2021, 154, 256-261.	0.4	2
6	Patient perspectives of pain mitigation strategies for adult vaccine injections. Canadian Journal of Pain, 2021, 5, 183-191.	0.6	2
7	Pharmacists as immunizers to <u>Improve</u> coverage and provider/recipient satisfaction: <u>A</u> prospective, <u>C</u> ontrolled <u>C</u> ommunity <u>E</u> mbedded <u>S</u> tudy with vaccine <u>S</u> with low coverage rates (the Improve ACCESS Study): Study summary and anticipated significance. Canadian Pharmacists Journal. 2020. 153. 88-94.	0.4	6
8	Medicationâ€related criteria in frailty assessment tools: A narrative review. Australasian Journal on Ageing, 2020, 39, e460-e465.	0.4	0
9	Pharmacist-led intervention to improve medication use in older inpatients using the Drug Burden Index: a study protocol for a before/after intervention with a retrospective control group and multiple case analysis. BMJ Open, 2020, 10, e035656.	0.8	5
10	Evaluation of the experiences and needs of users of a drug information resources website. Journal of the Medical Library Association: JMLA, 2020, 108, 270-277.	0.6	3
11	Point Prevalence Survey of Benzodiazepine and Sedative-Hypnotic Drug Use in Hospitalized Adult Patients. Canadian Journal of Hospital Pharmacy, 2020, 73, 193-201.	0.1	3
12	Opportunities for pharmacists to recommend and administer routine vaccines. Canadian Pharmacists Journal, 2019, 152, 401-405.	0.4	9
13	More or Less Medication: Is One Better than the Other?. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005530.	0.9	0
14	Clinical Pharmacy Considerations in Special Populations: Geriatrics. , 2019, , 803-814.		0
15	Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications. Drugs and Aging, 2019, 36, 29-37.	1.3	60
16	Drug Shortages: More than Just Background Noise. Canadian Journal of Hospital Pharmacy, 2019, 72, 3-4.	0.1	5
17	Patient experiences with influenza immunizations administered by pharmacists. Human Vaccines and Immunotherapeutics, 2018, 14, 706-711.	1.4	20
18	Polypharmacy and use of potentially inappropriate medications in long-term care facilities: does coordinated primary care make a difference?. International Journal of Pharmacy Practice, 2018, 26, 318-324.	0.3	13

SUSAN K BOWLES

#	Article	IF	CITATIONS
19	Pharmacists as vaccinators: An analysis of their experiences and perceptions of their new role. Human Vaccines and Immunotherapeutics, 2018, 14, 471-477.	1.4	28
20	Pharmacists' immunization experiences, beliefs, and attitudes in New Brunswick, Canada. Pharmacy Practice, 2018, 16, 1310.	0.8	15
21	Evidence for pharmacist vaccination. Canadian Pharmacists Journal, 2018, 151, 301-304.	0.4	10
22	Evaluation of the impact of immunization policies, including the addition of pharmacists as immunizers, on influenza vaccination coverage in Nova Scotia, Canada: 2006 to 2016. BMC Public Health, 2018, 18, 787.	1.2	25
23	The impact of pharmacists as immunizers in Collaborative cOmmunity Offsite Pharmacy Practice (CO-OPP Phase 1). Canadian Pharmacists Journal, 2018, 151, 29-32.	0.4	3
24	Falls and long-term care: a report from the care by design observational cohort study. BMC Family Practice, 2018, 19, 73.	2.9	48
25	Multimodal Pain Management in Older Elective Arthroplasty Patients. Geriatric Orthopaedic Surgery and Rehabilitation, 2017, 8, 151-154.	0.6	14
26	Impact of pharmacists as immunizers on influenza vaccination coverage in Nova Scotia, Canada. Human Vaccines and Immunotherapeutics, 2016, 12, 1225-1228.	1.4	27
27	Polypharmacy. , 2016, , 41-54.		Ο
28	Impact of pharmacists as immunizers on influenza vaccination coverage in the community-setting in Nova Scotia, Canada: 2013-2015. Journal of Pharmaceutical Policy and Practice, 2016, 9, 32.	1.1	15
29	Innovative Collaborative Practice to Optimize Pharmacotherapy for Frail Older Patients. Canadian Journal of Hospital Pharmacy, 2014, 67, 373-8.	0.1	1
30	Validating administrative data for the detection of adverse events in older hospitalized patients. Drug, Healthcare and Patient Safety, 2014, 6, 101.	1.0	20
31	Drug-induced osteoporosis in the older adult. Aging Health, 2010, 6, 501-518.	0.3	12
32	Efficacy of Natural Health Products in Treating Osteoporosis: What is the Quality of Internet Patient Advice?. Annals of Pharmacotherapy, 2009, 43, 899-907.	0.9	15
33	Use of wet nebulized inhaled respiratory medications under criteria-based reimbursement guidelines in a publicly funded seniors' pharmacare program in Nova Scotia, Canada. American Journal of Geriatric Pharmacotherapy, 2007, 5, 120-128.	3.0	4
34	Natural Health Products in the Prevention and Treatment of Osteoporosis: Systematic Review of Randomized Controlled Trials. Annals of Pharmacotherapy, 2006, 40, 836-849.	0.9	46
35	Comparison of a Frail-Friendly Nomogram with Physician-Adjusted Warfarin Dosage for Prophylaxis after Orthopaedic Surgery on a Geriatric Rehabilitation Unit. Canadian Journal on Aging, 2005, 24, 443-447.	0.6	0
36	Economic Evaluation of Oseltamivir Phosphate for Postexposure Prophylaxis of Influenza in Long-Term Care Facilities. Journal of the American Geriatrics Society, 2005, 53, 444-451.	1.3	25

SUSAN K BOWLES

#	Article	IF	CITATIONS
37	Pharmacists' Participation in an Inhaled Respiratory Medication Program: Reimbursement of Professional Fees. Annals of Pharmacotherapy, 2005, 39, 655-661.	0.9	11
38	Validation of Four Clinical Indicators of Preventable Drug-Related Morbidity. Annals of Pharmacotherapy, 2004, 38, 20-24.	0.9	8
39	Use of Oseltamivir During Influenza Outbreaks in Ontario Nursing Homes, 1999–2000. Journal of the American Geriatrics Society, 2002, 50, 608-616.	1.3	121
40	Drugs Mimicking Dementia. CNS Drugs, 2000, 14, 381-390.	2.7	11
41	Influenza outbreak in a long-term-care facility: Considerations for pharmacy. American Journal of Health-System Pharmacy, 1999, 56, 2303-2307.	0.5	10
42	Serum Concentrations of Salicylic Acid following Topically Applied Salicylate Derivatives. Annals of Pharmacotherapy, 1996, 30, 935-940.	0.9	63
43	Evaluation of the Pharmacokinetic and Pharmacodynamic Interaction Between Quinidine and Nifedipine. Journal of Clinical Pharmacology, 1993, 33, 727-731.	1.0	24
44	Neurologic Concerns in Long-Term Care. Journal of Pharmacy Practice, 1993, 6, 290-296.	0.5	0
45	Quinidine Does Not Alter Antipyrine Metabolism. Journal of Clinical Pharmacology, 1990, 30, 267-271.	1.0	5
46	Protein binding of cocaine in human serum. Pharmaceutical Research, 1988, 05, 440-442.	1.7	31
47	Inhibition of Drug Metabolism by Quinolone Antibiotics. Clinical Pharmacokinetics, 1988, 15, 194-204.	1.6	75
48	Increased Theophylline Concentrations Secondary to Ciprofloxacin. Drug Intelligence & Clinical Pharmacy, 1987, 21, 879-881.	0.4	30